OncoMatch/Clinical Trials/NCT07113613
Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy
Is NCT07113613 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
This study is a multicenter, single-arm, phase II clinical trial, aiming to evaluate the safety and efficacy of tumor bed dose escalation radiotherapy for patients with primary breast lesions achieving pCR (ypT0) after neoadjuvant chemotherapy and breast-conserving surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Excluded: BRCA1 mutated susceptibility gene
Excluded: BRCA2 mutated susceptibility gene
Disease stage
Required: Stage N3A
Excluded: Stage N3B, N3C
initially diagnosed as cT1-3N0-3a; Excluded: cT4, N3b-c
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: neoadjuvant therapy — neoadjuvant
Received the standard neoadjuvant treatment plan recommended by the guidelines based on molecular typing
Must have received: breast-conserving surgery
Underwent breast-conserving surgery, with negative surgical margins and a margin distance of ≥1mm
Cannot have received: chest radiotherapy
Had no previous chest radiotherapy
Cannot have received: radiotherapy in the neck, chest or ipsilateral axilla
history of radiotherapy in the neck, chest or ipsilateral axilla
Lab requirements
Blood counts
basically normal peripheral blood count
Kidney function
no significant abnormalities in kidney function
Liver function
no significant abnormalities in liver function
Cardiac function
no significant abnormalities in heart function; basically normal electrocardiogram
Met the basic requirements for adjuvant radiotherapy, including basically normal peripheral blood count, no significant abnormalities in heart, liver, and kidney functions, and basically normal electrocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07113613 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chest radiotherapy, radiotherapy in the neck, chest or ipsilateral axilla disqualifies patients from enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutated susceptibility gene is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutated susceptibility gene is an exclusion criterion.
What disease stage is eligible?
Stage N3A is required.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 30 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages